Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

Modified release formulation in immunotherapy – the tacrolimus case

N. Undre

Ann Transplant 2008; 13(1): 32-32 :: ID: 880186

Abstract

Tacrolimus, is a CNI marketed under the trade name Prograf[sup]®[/sup]; oral Prograf capsules are administered as a twice-daily dosing regimen. Poor compliance with dosing has been shown to be one of the factors associated with the incidence of transplant rejection and late graft loss and the likelihood for adherence is better with a once daily dosing regimen compared to that with twice daily dosing regimen. Advagraf has been developed as a once daily formulation of tacrolimus aimed at improving compliance with dosing and thereby decreasing the risk of late graft rejection and loss. Pharmacokinetics of Advagraf have been evaluated in stable adult kidney, liver and heart transplant recipients as well as de novo liver and kidney transplant recipients. In stable patients following conversion from Prograf to Advagraf on a 1:1 (mg:mg) total daily dose, systemic exposure to tacrolimus over 24 hour (AUC0-24) was similar. In de novo kidney and liver transplant patients AUC[sub]0-24[/sub] of tacrolimus for Advagraf on Day 1 was 30% and 50% lower respectively, when compared with that for Prograf at equivalent doses. By Day 4, systemic exposure is similar with both formulations. Efficacy and safety profile of Advagraf was comparable to Prograf with a patient follow up of up to 3 years. There was good correlation between AUC[sub]0-24[/sub] and trough level (C[sub]24[/sub]) of tacrolimus for Advagraf and the relationship between these two parameters is similar to that for Prograf, thus, therapy for both formulations can be optimised using the same therapeutic monitoring concept.

Keywords: Tacrolimus, Liver, Kidney Transplant

0 Comments

In Press

20 Jan 2022 : Original article  

Impact on Waitlist Outcomes from Changes in the Medical Eligibility of Candidates for Simultaneous Liver-Ki...

Ann Transplant In Press; DOI: 10.12659/AOT.934850  

19 Jan 2022 : Original article  

Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in He...

Ann Transplant In Press; DOI: 10.12659/AOT.933420  

18 Jan 2022 : Original article  

PLGA+Fe₃O₄+PFP Nanoparticles Drug-Delivery Demonstrates Potential Anti-Tumor Effects on Tumor Cells

Ann Transplant In Press; DOI: 10.12659/AOT.933246  

17 Jan 2022 : Original article  

Impact of Thyroid Incidentaloma on Liver Transplant: A Study of 1010 Recipients at a Single Center

Ann Transplant In Press; DOI: 10.12659/AOT.934988  

Most Viewed Current Articles

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

22 Dec 2021 : Original article  

Comparison of Coronary Artery Calcium Scoring with Dobutamine Stress Echo for Detection of Coronary Artery ...

DOI :10.12659/AOT.934163

Ann Transplant 2021; 26:e934163

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

01 Dec 2021 : Original article  

Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-S...

DOI :10.12659/AOT.934175

Ann Transplant 2021; 26:e934175

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358